Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 3, 2020, regarding events occurring on February 26, 2020. The filing details the Compensation Committee's approval of 2019 annual bonuses, 2020 base salaries, bonus targets, and equity awards for named executive officers. The filing also notes the impending resignation of two senior executives.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and personnel changes.
Material Changes and Personnel Actions
- Executive Resignations: James P. Kelly (EVP, CFO, Treasurer) resigned effective March 15, 2020. Gian Piero Reverberi (SVP, Chief Commercial Officer) resigned effective March 16, 2020.
- 2019 Bonuses Awarded:
- Mihael Polymeropoulos (CEO): $675,000
- James P. Kelly (CFO): $288,622
- Gian Piero Reverberi (CCO): $270,901
- Gunther Birznieks (SVP, Business Development): $180,765
- Timothy Williams (SVP, General Counsel): $177,520
- 2020 Compensation Adjustments:
- CEO Mihael Polymeropoulos: Base salary set at $746,235 with an 80% target bonus.
- SVP Gunther Birznieks: Base salary set at $421,000 with a 40% target bonus.
- SVP Timothy Williams: Base salary set at $400,000 with a 40% target bonus.
Equity Awards and Vesting
On February 26, 2020, the company granted stock options and Restricted Stock Units (RSUs) to remaining named executive officers. The option exercise price was $11.32 per share.
| Officer | Option Shares | RSU Shares |
|---|---|---|
| Mihael Polymeropoulos (CEO) | 140,000 | 60,000 |
| Gunther Birznieks (SVP) | 70,000 | 30,000 |
| Timothy Williams (SVP) | 70,000 | 30,000 |
Vesting Schedule: Options vest 25% on February 26, 2021, with the remainder vesting monthly over 36 months. RSUs vest in four equal annual installments beginning March 1, 2021.
Outlook and Risks
The filing does not contain forward-looking guidance, management commentary on business outlook, or specific risk factors beyond the disclosed executive departures. The resignations of the CFO and Chief Commercial Officer within a two-day window represent a significant leadership transition.
Investor Verification Checklist
- Verify the appointment of a new Chief Financial Officer and Chief Commercial Officer to replace the resigning executives.
- Review the impact of the leadership changes on the company's commercial strategy and financial reporting continuity.
- Confirm the total dilution impact of the new equity grants (280,000 options and 120,000 RSUs) relative to the outstanding share count.
- Check subsequent filings for details on the transition of duties for the CFO and CCO roles.